Research and Markets (http://www.researchandmarkets.com/research/q5wnt2/fragile_x) has announced the addition of the "Fragile X Syndrome-Pipeline Insights" subscription to their offering.
This Fragile X Syndrome-Pipeline Insights report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Fragile X Syndrome.
This report provides information on the therapeutic development based on the Fragile X Syndrome dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information.
The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.
Key Topics Covered:
- Fragile X Syndrome Overview
- Fragile X Syndrome Pipeline Therapeutics
- Fragile X Syndrome Therapeutics under Development by Companies
- Fragile X Syndrome Late Stage Products (Filed and Phase III)
- Comparative Analysis
- Fragile X Syndrome Mid Clinical Stage Products (Phase II)
- Comparative Analysis
- Fragile X Syndrome Early Clinical Stage Products (Phase I and IND Filed)
- Comparative Analysis
- Fragile X Syndrome Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Fragile X Syndrome - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Fragile X Syndrome - Discontinued Products
- Fragile X Syndrome - Dormant Products
- Companies Involved in Therapeutics Development for Fragile X Syndrome
- Appendix
For more information visit http://www.researchandmarkets.com/research/q5wnt2/fragile_x